Thymosin alpha-1 has a long research history across immune, infectious-disease, cancer, and critical-care settings.
The human literature is disease-specific and inconsistent; PCAC voted against both reviewed forms, and a large 2025 sepsis trial found no mortality benefit.
What a visitor should know.
Technical details: aliases, tracked claims, and data record
5 names in this peptide family.
Thymosin alpha-1, thymalfasin, free base, and acetate references resolve to one family without transferring findings across products, routes, populations, or diseases.
4 evidence questions.
Human benefitMultiple human trialsDoes Thymosin alpha-1 have established human clinical benefit for hepatitis b, hepatitis c, hiv, covid-19, vaccine response, cancers, sepsis, transplant infections, copd, and me/cfs?
FDA approvalNo FDA approval identifiedIs Thymosin alpha-1 FDA approved?
503A statusRegulatory recordIs Thymosin alpha-1 on FDA's final 503A Bulks List or generally permitted because of committee activity?
Identity transferIdentity-sensitiveAre every product, alias, form, and related compound labeled Thymosin alpha-1 automatically interchangeable?
See every Thymosin alpha-1 evidence question →Open the machine-readable record ↗PCAC did not recommend thymosin alpha-1 for the 503A Bulks List
The committee voted 4–17 against recommending each of the reviewed free-base and acetate forms.
FDA received an unfavorable expert recommendation after a broad, use-specific review.
The vote was non-binding and did not itself create a final legal change or decide FDA approval.
How the FDA record developed.
This timeline separates early nominations and scientific reviews from committee votes and final FDA decisions.
PCAC did not recommend thymosin alpha-1 for the 503A Bulks List
The committee voted 4–17 against recommending each of the reviewed free-base and acetate forms.
Read the source ↗FDA completed its scientific briefing
FDA evaluated thymosin alpha-1-related substances across viral, immune, cancer, sepsis, pulmonary, and fatigue-related uses.
Read the source ↗FDA challenged COVID-19 marketing claims for thymosin alpha-1
FDA warned a firm marketing thymosin alpha-1 products for COVID-19 that the products were unapproved and misbranded.
Read the source ↗Thymosin alpha-1 entered FDA's 503A nomination record
Thymosin alpha-1-related substances were nominated for multiple uses; the nominations were later withdrawn and FDA continued evaluation on its own initiative.
Read the source ↗What has actually been studied?
Human studies appear on the left. Animal, cell, and laboratory studies appear on the right because they cannot establish that a treatment works in people.
Among 1,106 adults with sepsis, thymosin alpha-1 did not reduce 28-day mortality or improve secondary outcomes versus placebo. This trial post-dates the 2024 committee vote and does not establish benefit for other diseases.
Read the study on PubMed ↗In 97 patients, the complete-response difference favored thymosin alpha-1 numerically but was not statistically significant. The study does not establish a general immune or antiviral benefit.
Read the study on PubMed ↗Immune-mechanism findings do not establish clinical benefit across the many proposed diseases and compounded-product contexts.
Read the FDA review ↗Important unknowns.
- FDA identified immunogenicity, impurity, and active-ingredient characterization concerns for compounded products.
- Published trials span many diseases, products, populations, and eras; their results should not be collapsed into one general benefit claim.
- A large 2025 sepsis trial found no mortality benefit, illustrating why disease-specific human outcomes matter.
These are evidence and regulatory uncertainties, not an individualized assessment of whether a treatment is appropriate.
Read the original sources.
Technical change history and comparison data
4 dated changes. 0 comparison groups.
These records show what each source added and whether it changed Peplyst's public conclusion.